Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022		Jan. 31, 2021	Jan. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (157,560)		$ (192,194)	$ (130,741)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	30,009		111,846	40,872
Amortization of intangible assets	665		222	0
Depreciation expense	543		0	0
Amortization of deferred contract acquisition costs	33,368		18,469	7,960
Unrealized foreign exchange (gain) loss	20,389		(24,322)	4,257
Other non-cash expense	197		458	122
Changes in assets and liabilities:
Accounts receivable	(38,223)		(14,745)	(13,457)
Prepaid expenses and other current assets	(8,219)		677	(5,743)
Costs deferred related to contract acquisition	(42,575)		(34,137)	(15,223)
Other long-term assets	(3,374)		252	(1,128)
Accounts payable	1,877		1,474	914
Accrued expenses and other current liabilities	13,953		733	3,395
Accrued compensation and benefits	19,755		4,646	5,791
Deferred revenue	79,074		52,382	41,950
Other long-term liabilities	307		659	865
Net cash used in operating activities	(49,814)		(73,580)	(60,166)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of short-term investments	(100,031)		0	0
Proceeds from maturities of short-term investments	50,000		0	0
Purchases of property and equipment	(3,541)		0	0
Payments for business combination, net of cash acquired and consideration withheld in an escrow	(323)		0	0
Payments for asset acquisitions	0		(933)	0
Other investing activities	0		91	0
Net cash used in investing activities	(53,895)		(842)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from initial public offering, net of underwriting discounts	654,552		0	0
Proceeds from the issuance of common stock upon exercise of stock options, including early exercises, net of repurchases	25,354		13,765	3,088
Proceeds from warrants exercised	86		0	0
Net proceeds from Series E preferred stock financing	0		0	268,177
Repurchase of common stock in a tender offer	(590)		(820)	0
Contributions received from noncontrolling interests	26,450		0	0
Payments of deferred offering costs	(4,667)		0	0
Net cash provided by financing activities	701,185		12,945	271,265
Impact of foreign exchange on cash, cash equivalents and restricted cash	6,846		1,000	(226)
Net increase (decrease) in cash, cash equivalents and restricted cash	604,322		(60,477)	210,873
Cash, cash equivalents and restricted cash at beginning of period	282,850		343,327	132,454
Cash, cash equivalents and restricted cash at end of period	887,172		282,850	343,327
Supplemental disclosure of cash flow information:
Cash paid for income taxes	1,310		1,901	1,986
Cash donations	1,000		0	0
Supplemental disclosure of non-cash investing and financing activities:
Vesting of early exercised stock options	7,212		2,838	671
Issuance of common stock upon conversion of preferred stock	424,904		242	0
Unpaid property and equipment in accrued expenses	273		0	0
Unpaid deferred offering costs	40		0	0
Reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets to the amounts shown in the consolidated statements of cash flows above:
Cash and cash equivalents	884,672	[1]	282,850	343,327
Restricted cash	2,500		0	0
Total cash, cash equivalents and restricted cash	$ 887,172		$ 282,850	$ 343,327

[1] (1) As of January 31, 2022, the consolidated balance sheet includes assets and liabilities of the consolidated variable interest entity, GitLab Information Technology (Hubei) Co., LTD (“JiHu”), of $17.7 million and $3.7 million, respectively. The assets of JiHu can be used only to settle obligations of JiHu and creditors of JiHu do not have recourse against the general credit of the Company. Refer to “Note 10. Joint Venture and Majority Owned Subsidiary” for further discussion.